Travere Therapeutics Inc
$ 39.54
-3.44%
16 Apr - close price
- Market Cap 3,652,302,000 USD
- Current Price $ 39.54
- High / Low $ 40.00 / 38.12
- Stock P/E N/A
- Book Value 1.26
- EPS -0.57
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.58 %
- 52 Week High 43.31
- 52 Week Low 13.88
About
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Analyst Target Price
$48.21
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-30 | 2025-07-30 | 2025-05-05 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-06 | 2024-03-12 | 2023-11-07 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0.37 | 0.59 | 0.13 | -0.19 | -0.47 | -0.7 | -0.91 | -1.76 | -1.18 | -1.17 | -1.13 | -1.27 |
| Estimated EPS | -0.04 | -0.29 | -0.2715 | -0.3943 | -0.3786 | -0.68 | -0.86 | -0.99 | -1.27 | -0.14 | -1.16 | -1.17 |
| Surprise | 0.41 | 0.88 | 0.4015 | 0.2043 | -0.0914 | -0.02 | -0.05 | -0.77 | 0.09 | -1.03 | 0.03 | -0.1 |
| Surprise Percentage | 1025% | 303.4483% | 147.8821% | 51.8133% | -24.1416% | -2.9412% | -5.814% | -77.7778% | 7.0866% | -735.7143% | 2.5862% | -8.547% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TVTX
2026-04-16 20:09:12
Travere Therapeutics, Inc. SVP and Chief Accounting Officer Sandra Calvin reported exercising employee stock options for 15,250 shares and subsequently selling 21,977 shares of common stock at $41.07 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2025. After these transactions, Calvin directly holds 42,353 shares of Travere Therapeutics common stock, indicating a routine liquidity management event rather than a signal on company fundamentals.
2026-04-16 20:09:12
Travere Therapeutics director Roy D. Baynes exercised 32,750 stock options and subsequently sold all 32,750 shares in open-market transactions. These transactions, conducted under a Rule 10b5-1 trading plan adopted in November 2025, involved sales at prices between $41.07 and $42.12 per share. Following these sales, Baynes directly owns 37,500 shares of Travere Therapeutics common stock.
2026-04-16 11:09:12
Peter Heerma, an insider at Travere Therapeutics (NASDAQ:TVTX), sold 7,215 shares of the company's stock for over $302,000 to cover tax withholding on vested awards. This sale, along with other insider selling, follows the FDA's full approval of Filspari, which caused a significant stock jump and multiple analyst upgrades. Despite the insider sales, analysts have a "Moderate Buy" consensus rating with an average target price of $42.50 for TVTX.
2026-04-16 09:09:12
Travere Therapeutics received FDA approval for its drug FILSPARI to treat Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease, expanding its use beyond IgA nephropathy. This approval significantly broadens the potential patient base for FILSPARI, making it the first and only approved medicine for this condition. While this development is a positive catalyst for Travere, the company still faces risks associated with heavy reliance on a single drug and potential pricing pressures.
2026-04-16 03:40:20
Elizabeth Reed, an insider at Travere Therapeutics (NASDAQ:TVTX), sold 44,715 shares of the company's stock on April 14th for over $1.84 million, reducing her stake by 28.53%. This sale was conducted under a Rule 10b5-1 plan to cover tax withholdings from vested equity awards. The company recently received FDA approval for Filspari in FSGS, significantly expanding its market, leading to a share surge and multiple analyst price target upgrades, despite the stock's current negative P/E ratio and high volatility.
2026-04-16 02:40:21
Peter Heerma, Travere Therapeutics' Chief Commercial Officer, was granted 14,000 performance restricted stock units (PSUs) on April 13, 2026, following FDA approval of FILSPARI. Subsequently, he sold 7,215 shares for $41.9288 per share on April 14, 2026, specifically to cover tax withholding obligations associated with these vested units. After these transactions, Heerma directly holds 138,608 shares of Travere common stock.
